Your browser doesn't support javascript.
loading
Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank.
Jefferies, Matthew T; Pope, Christopher S; Kynaston, Howard G; Clarke, Alan R; Martin, Richard M; Adams, Josephine C.
Afiliación
  • Jefferies MT; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, UK.
  • Pope CS; Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
  • Kynaston HG; School of Biochemistry, University of Bristol, Bristol, UK.
  • Clarke AR; Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
  • Martin RM; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, UK.
  • Adams JC; School of Social and Community Medicine, University of Bristol, Bristol, UK.
Biomark Cancer ; 9: 1179299X17710944, 2017.
Article en En | MEDLINE | ID: mdl-28607544
Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. We examined fascin-1 by immunohistochemistry in tumour specimens from the Wales Cancer Bank in comparison with nuclear-located ETS-related gene (ERG), an emerging marker for aggressive prostate cancer. Fascin-1 was elevated in focal areas of a minority of tumours, yet fascin-1-positivity did not differentiate tumours of low-, intermediate-, or high-risk Gleason scores and did not correlate with PSA status or biochemical relapse after surgery. Stromal fascin-1 correlated with high Gleason score. Nuclear ERG was upregulated in tumours but not in stroma. The complexities of fascin-1 status indicate that fascin-1 is unlikely to provide a suitable biomarker for prediction of aggressive prostate cancers.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Biomark Cancer Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Biomark Cancer Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos